CD Formulation is dedicated to developing innovative nucleic acid-based technologies that facilitate the production of compounds with exceptional binding affinity and chemical/biological stability. Through our advanced nucleic acid preparation technology, we offer tailored BNA synthesis services to address the unique requirements of researchers around the globe.
To date, a third generation of BNA (Bridged Nucleic Acid), referred to as 2', 4'-BNA-NC, has been developed. This new variant can be easily integrated into the oligonucleotide chain, facilitating the design of BNA-hybridizing oligonucleotides that meet the demand for a very high degree of sequence-specific hybridization to nucleic acids. BNA's high affinity for nucleic acids and its nuclease resistance make it an exceptional tool for the development of high-value assays and therapeutic products.
Our BNA customization services encompass all stages, from custom synthesis to the final product. This includes precise purification of BNA, rigorous quality control, and flexible batch production. CD Formulation is dedicated to delivering high-quality BNA products tailored to customer needs. We ensure each batch meets functional standards through optimized synthesis and purification, while our quality control adheres to strict industry standards for purity and functionality.
BNA oligonucleotides enhance primer and probe design flexibility. They can be combined with DNA, RNA, and other nucleic acid analogs using standard phosphoramidite synthesis. Additionally, they can be easily labeled or modified with conventional labels like DIG, fluorescent dyes, biotin, and amino junctions.
Purification of bridged nucleic acids is typically conducted using a HPLC technology platform. Our technology platform optimizes the separation of nucleic acids of varying lengths and sequences by employing different stationary and mobile phase conditions.
Quality control of biologically active nucleic acids (BNAs) is crucial for their development and production, ensuring efficiency and reliability. This process involves assessing product purity, verifying sequence accuracy, and analyzing physicochemical properties. Stringent quality control minimizes defects and impurities, enhancing stability and biocompatibility.
Fig.1 Flow chart of BNA preparation. (CD Formulation)
Determine the required BNA sequence, along with the necessary chemical modifications and the length of the BNA. Select the appropriate sequence based on the experimental requirements and design objectives.
Use bioinformatics tools to design a highly specific and stable oligonucleotide sequence for the intended application.
BNA is synthesized through chemical processes and subsequently purified to yield a highly pure product.
After synthesis, rigorous quality control measures are implemented, including mass spectrometry and HPLC, to verify the purity and accuracy of the BNA.
Within CD Formulation's specialized BNA synthesis technology and analysis platform, we utilize several advanced techniques for precise synthesis.
Solid Phase Synthesis Technology Platform | Enzymatic Synthesis Technology Platform |
State-of-the-art synthesis methods are used to optimize synthesis steps and increase BNA yields. | Enzyme synthesis efficiently applies biocatalytic processes for synthesizing complex molecules. |
HPLC Platform | MS Platform |
Evaluation of BNA purity and consistency. | For accurate mass determination of BNA molecules. |
Technology: Synthetic bridged nucleic acids (BNAs) by chemical synthesis technology
Journal: International Journal of Molecular Sciences
IF: 4.9
Published: 2021
Results:
This study designed splice-switching oligonucleotides modified with LNA, AmNA, and GuNA, varying in length and content. The authors measured the melting temperature (Tm) of each SSO to evaluate its binding affinity to the RNA strand. The authors found that both AmNA-modified SSOs and GuNA-modified SSOs had higher exon skipping activity than LNA-modified SSOs, but each class of BNAs had to be designed appropriately in terms of length and modification content.
Fig.2 Structures of BNA analogs. (Shimo T, et al., 2021)
CD Formulation offers Bridged Nucleic Acid (BNA) customization services designed to meet diverse research and application needs. Feel free to contact us and we will provide customized solutions to assist in research and product development.
References